Phaseline

Companies › Jiangsu Aosaikang Pharmaceutical

Jiangsu Aosaikang Pharmaceutical: clinical trials, targets and expected readouts

5 active drug programs in 7 registered trials: 3 Phase 1, 2 Phase 3, 2 Phase 2; Oncology, Infectious disease, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASKC202
EGFR tyrosine kinase inhibitor
EGFRPhase 3Locally Advanced or Metastatic NSCLC; Advanced Solid TumorDec 2026
ASK0912 for Injection
Monobactam antibiotic
–Phase 2Ventilator-associated Bacterial Pneumonia (VABP)Oct 2027
ASKC200–Phase 2Osteoarthritis (OA) of the Knee–
ASK120067 (Limertinib)
EGFR tyrosine kinase inhibitor
EGFRPhase 1Advanced Solid TumorDec 2026
ASKB589 Injection–Phase 1Malignant Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04632108ASKB589 InjectionPhase 1Malignant Solid TumorOncologyOct 2025
NCT07742852ASKC200Phase 2Osteoarthritis (OA) of the KneeImmunologyApr 2026
NCT05306132ASKC202Phase 1Advanced Solid TumorOncologyDec 2026
NCT05306132ASK120067 (Limertinib)Phase 1Advanced Solid TumorOncologyDec 2026
NCT07759934ASK0912 for InjectionPhase 2Ventilator-associated Bacterial Pneumonia (VABP)Infectious diseaseOct 2027
NCT07109531ASKC202Phase 3Locally Advanced or Metastatic NSCLCOncologyOct 2027
NCT07109531ASKC202Phase 3Locally Advanced or Metastatic NSCLCOncologyOct 2027

Targets

EGFR (2)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Nanjing Sanhome Pharmaceutical Jiangsu Alphamab Biopharmaceuticals HC Biopharma Wayshine Biopharm ArriVent BioPharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.